SCHEMBL3178391

SCHEMBL3178391

CC(C)=CC(=O)Oc1cc2ccccc2cc1OC(=O)C=C(C)C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.46
POLB P06746 2/20 0.46
KDM4E B2RXH2 3/20 0.43
HPGD P15428 2/20 0.43
ALDH1A1 P00352 2/20 0.43
NCEH1 Q6PIU2 1/20 0.42
IRAK4 Q9NWZ3 1/20 0.39
MAPT P10636 3/20 0.37
HSD17B10 Q99714 1/20 0.37
CA12 O43570 1/20 0.37
CA9 Q16790 1/20 0.37
TDP1 Q9NUW8 2/20 0.36
GAA P10253 1/20 0.36
APEX1 P27695 1/20 0.36
RECQL P46063 1/20 0.36
BLM P54132 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MEN1 O00255 2/20 0.36
HTR1A P08908 1/20 0.36
NPC1 O15118 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28446712 0.87 KDM4E (0.40) KMT2APOLBKDM4EHPGDALDH1A1
SCHEMBL3186605 0.84 KDM4E (0.46) KMT2AKDM4EHPGDALDH1A1MAPT
SCHEMBL28446710 0.83 KMT2A (0.38) KMT2APOLBKDM4EHPGDALDH1A1
SCHEMBL1405221 0.80 ELANE (0.47) KMT2AKDM4EHPGDALDH1A1MAPT
SCHEMBL17138183 0.79 KMT2A (0.52) KMT2AMEN1NPC1
SCHEMBL6906339 0.78 CA12 (0.55) KMT2APOLBKDM4EHPGDALDH1A1
SCHEMBL9841768 0.78 TDP1 (0.43) KMT2AKDM4EHPGDALDH1A1MAPT
SCHEMBL3188972 0.77 MTNR1A (0.44) ALDH1A1NCEH1MAPTHSD17B10GAA
SCHEMBL12245559 0.77 KDM4E (0.52) KMT2AKDM4EHPGDALDH1A1NCEH1
SCHEMBL17673150 0.76 KDM4E (0.40) KMT2APOLBKDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008004788-A1 NOVEL DERIVATIVES OF CYCLIC COMPOUND AND THE USE THEREOF WONKISOPHARM CO., LTD. (KR) 2008-01-10 WO claimed
CN-106309421-B Pharmaceutical composition and cosmetic composition 沃凯索法株式会社 2020-08-25 CN disclosed
US-8420853-B2 Derivatives of cyclic compound and the use thereof Wonkisopharm Co., Ltd (KR) 2013-04-16 US disclosed
US-20100022461-A1 Novel Derivatives of Cyclic Compound And The Use Thereof WONKISOPHARM CO., LTD. (KR) 2010-01-28 US disclosed
WO-2008004788-A1 NOVEL DERIVATIVES OF CYCLIC COMPOUND AND THE USE THEREOF WONKISOPHARM CO., LTD. (KR) 2008-01-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022461-A1 Novel Derivatives of Cyclic Compound And The Use Thereof TYR, MC1R, PDE7A KMT2A 3230/4885POLB 2254/4885KDM4E 1668/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.